Pulmonary 5-HT
        2B receptor expression in fibrotic interstitial lung diseases.

Anna Löfdahl; Annika Nybom; Jenny Wigén; Göran Dellgren; Hans Brunnström; Christina Wenglén; Gunilla Westergren-Thorsson

doi:10.1016/j.acthis.2023.152024

Pulmonary 5-HT 2B receptor expression in fibrotic interstitial lung diseases.

Anna Löfdahl, Annika Nybom, Jenny Wigén, Göran Dellgren, Hans Brunnström, Christina Wenglén, Gunilla Westergren-Thorsson

Research output: Contribution to journal › Article › peer-review

Abstract

Pulmonary fibrosis is a severe condition in interstitial lung diseases (ILD) such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-ILD, where the underlying mechanism is not well defined and with no curative treatments available. Serotonin (5-HT) signaling via the 5-HT 2B receptor has been recognized as a promising preclinical target for fibrosis. Despite this, the involvement of the 5-HT 2B receptor in fibrotic ILD is widely unexplored. This work highlights the spatial pulmonary distribution of the 5-HT 2B receptor in patients with IPF and systemic sclerosis-ILD. We show that the 5-HT 2B receptor is located in typical pathological structures e.g. honeycomb cysts and weakly in fibroblast foci. Together with immunohistochemistry and immunofluorescence stainings of patient derived distal lung tissues, we identified cell targets for 5-HT 2B receptor interference in type II alveolar epithelial cells, endothelial cells and M2 macrophages. Our results emphasize the role of 5-HT 2B receptor as a target in lung fibrosis, warranting further consideration in targeting fibrotic ILDs.

Original language	English
Article number	152024
Pages (from-to)	1-8
Journal	Acta Histochemica
Volume	125
Issue number	3
DOIs	https://doi.org/10.1016/j.acthis.2023.152024
Publication status	Published - 2023

Subject classification (UKÄ)

Respiratory Medicine and Allergy

Access to Document

10.1016/j.acthis.2023.152024

Cite this

@article{0f2f1de9a96242858451467fea913b30,

title = "Pulmonary 5-HT 2B receptor expression in fibrotic interstitial lung diseases.",

abstract = "Pulmonary fibrosis is a severe condition in interstitial lung diseases (ILD) such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-ILD, where the underlying mechanism is not well defined and with no curative treatments available. Serotonin (5-HT) signaling via the 5-HT 2B receptor has been recognized as a promising preclinical target for fibrosis. Despite this, the involvement of the 5-HT 2B receptor in fibrotic ILD is widely unexplored. This work highlights the spatial pulmonary distribution of the 5-HT 2B receptor in patients with IPF and systemic sclerosis-ILD. We show that the 5-HT 2B receptor is located in typical pathological structures e.g. honeycomb cysts and weakly in fibroblast foci. Together with immunohistochemistry and immunofluorescence stainings of patient derived distal lung tissues, we identified cell targets for 5-HT 2B receptor interference in type II alveolar epithelial cells, endothelial cells and M2 macrophages. Our results emphasize the role of 5-HT 2B receptor as a target in lung fibrosis, warranting further consideration in targeting fibrotic ILDs. ",

author = "Anna L{\"o}fdahl and Annika Nybom and Jenny Wig{\'e}n and G{\"o}ran Dellgren and Hans Brunnstr{\"o}m and Christina Wengl{\'e}n and Gunilla Westergren-Thorsson",

note = "Copyright {\textcopyright} 2023. Published by Elsevier GmbH.",

year = "2023",

doi = "10.1016/j.acthis.2023.152024",

language = "English",

volume = "125",

pages = "1--8",

journal = "Acta Histochemica",

issn = "0065-1281",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Pulmonary 5-HT 2B receptor expression in fibrotic interstitial lung diseases.

AU - Löfdahl, Anna

AU - Nybom, Annika

AU - Wigén, Jenny

AU - Dellgren, Göran

AU - Brunnström, Hans

AU - Wenglén, Christina

AU - Westergren-Thorsson, Gunilla

PY - 2023

Y1 - 2023

N2 - Pulmonary fibrosis is a severe condition in interstitial lung diseases (ILD) such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-ILD, where the underlying mechanism is not well defined and with no curative treatments available. Serotonin (5-HT) signaling via the 5-HT 2B receptor has been recognized as a promising preclinical target for fibrosis. Despite this, the involvement of the 5-HT 2B receptor in fibrotic ILD is widely unexplored. This work highlights the spatial pulmonary distribution of the 5-HT 2B receptor in patients with IPF and systemic sclerosis-ILD. We show that the 5-HT 2B receptor is located in typical pathological structures e.g. honeycomb cysts and weakly in fibroblast foci. Together with immunohistochemistry and immunofluorescence stainings of patient derived distal lung tissues, we identified cell targets for 5-HT 2B receptor interference in type II alveolar epithelial cells, endothelial cells and M2 macrophages. Our results emphasize the role of 5-HT 2B receptor as a target in lung fibrosis, warranting further consideration in targeting fibrotic ILDs.

AB - Pulmonary fibrosis is a severe condition in interstitial lung diseases (ILD) such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-ILD, where the underlying mechanism is not well defined and with no curative treatments available. Serotonin (5-HT) signaling via the 5-HT 2B receptor has been recognized as a promising preclinical target for fibrosis. Despite this, the involvement of the 5-HT 2B receptor in fibrotic ILD is widely unexplored. This work highlights the spatial pulmonary distribution of the 5-HT 2B receptor in patients with IPF and systemic sclerosis-ILD. We show that the 5-HT 2B receptor is located in typical pathological structures e.g. honeycomb cysts and weakly in fibroblast foci. Together with immunohistochemistry and immunofluorescence stainings of patient derived distal lung tissues, we identified cell targets for 5-HT 2B receptor interference in type II alveolar epithelial cells, endothelial cells and M2 macrophages. Our results emphasize the role of 5-HT 2B receptor as a target in lung fibrosis, warranting further consideration in targeting fibrotic ILDs.

U2 - 10.1016/j.acthis.2023.152024

DO - 10.1016/j.acthis.2023.152024

M3 - Article

C2 - 36958084

SN - 0065-1281

VL - 125

SP - 1

EP - 8

JO - Acta Histochemica

JF - Acta Histochemica

IS - 3

M1 - 152024

ER -

Pulmonary 5-HT 2B receptor expression in fibrotic interstitial lung diseases.

Abstract

Subject classification (UKÄ)

Access to Document

Fingerprint

Cite this